Showing results (1-10 of 35) with videos related to
Sort By:
Pageof 4
Antimicrobial Resistance and Infection Control|August 25, 2024
Predicting early appropriate therapy for patients infected by carbapenem-resistant Gram-negative pathogens in intensive care units in ItalyMatteo Bassetti, Gianpaola Monti, Anne Santerre Henriksen, et al.International Journal of Antimicrobial Agents|January 15, 2013
In vivo efficacy of telavancin/colistin combination therapy in a Galleria mellonella model of Acinetobacter baumannii infectionMichael Hornsey, Lynette Phee, Christopher Longshaw, et al.Antimicrobial Agents and Chemotherapy|April 12, 2012
In vitro activity of telavancin in combination with colistin versus Gram-negative bacterial pathogensMichael Hornsey, Christopher Longshaw, Lynette Phee, et al.Jac-Antimicrobial Resistance|July 5, 2021
In vitro activity of the siderophore cephalosporin, cefiderocol, against molecularly characterized, carbapenem-non-susceptible Gram-negative bacteria from EuropeChristopher Longshaw, Davide Manissero, Masakatsu Tsuji, et al.The Journal of Antimicrobial Chemotherapy|March 15, 2022
Cefiderocol: EUCAST criteria for disc diffusion and broth microdilution for antimicrobial susceptibility testingErika Matuschek, Christopher Longshaw, Miki Takemura, et al.Journal of Global Antimicrobial Resistance|July 30, 2021
In vitro activity of cefiderocol and comparators against Gram-negative bacterial isolates from a series of surveillance studies in England: 2014-2018Vanya Gant, Abid Hussain, Malcolm Bain, et al.Journal of Global Antimicrobial Resistance|May 21, 2021
In vitro activity of cefiderocol and comparators against isolates of Gram-negative pathogens from a range of infection sources: SIDERO-WT-2014-2018 studies in ItalyStefano Stracquadanio, Eleonora Torti, Christopher Longshaw, et al.Jac-Antimicrobial Resistance|July 5, 2021
In vitro activity of cefiderocol and comparators against isolates of Gram-negative pathogens from a range of infection sources: SIDERO-WT-2014-2018 studies in FranceThierry Naas, Gerard Lina, Anne Santerre Henriksen, et al.Jac-Antimicrobial Resistance|July 28, 2021
Erratum to: In vitro activity of cefiderocol and comparators against isolates of Gram-negative pathogens from a range of infection sources: SIDERO-WT-2014-2018 studies in FranceThierry Naas, Gerard Lina, Anne Santerre Henriksen, et al.Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|July 23, 2021
In vitro activity of the novel siderophore cephalosporin, cefiderocol, in Gram-negative pathogens in Europe by site of infectionFrancisco Javier Candel, Anne Santerre Henriksen, Christopher Longshaw, et al.Pageof 4